DEVELOPMENT PIPELINE
Explore our Active Programs
BRAIN-DRUG DELIVERY TECHNOLOGIES
Psycheceutical is currently developing products for neuropsychiatric and neurocognitive disorders which are at clinical and pre-clinical stages.
DEVELOPMENT PIPELINE
Our goal is to employ our patented brain-drug delivery strategies to clinically advance FDA-approved psychedelics and Generation 3 therapeutics for neuropsychiatric and neurocognitive disorders in the treatment of mental health and mood disorders.
PSY-007
KETAMINE
INDICATION:
Post Traumatic Stress Disorder (PTSD)
STAGE:
Phase I Clinical Trials
Our additional IP uniquely focuses on development of brain-drug delivery to combat traumatic brain injuries as we seek to improve functional outcomes for those who suffer from TBI-related conditions.